Biofidelity Announces Formation of Scientific Advisory Board

New Scientific Advisory Board combines decades of industry, academic and patient advocacy oncology leadership to help guide development & launch of Biofidelity's breakthrough ASPYRE diagnostic technology

Cambridge, UK, 15 July 2021 – Biofidelity Ltd, the cancer diagnostics company, today announces the members of its newly-formed Scientific Advisory Board (SAB) with the appointments of leaders from the clinical, pharmaceutical and patient advocacy fields. Initial members include:

- Dr. Mace Rothenberg, former CMO, Pfizer
- Dr. Hesham Abdullah, Head of Oncology Global Clinical Development, GSK
- Dr. Jerald Radich, Professor & Kurt Enslein Endowed Chair, Fred Hutchinson Cancer Research Center
- Andrea Conners, Executive Director, Patient Empowerment Network
- Phylicia L. Woods, Executive Director, Cancer Policy Institute, Cancer Support Community

The SAB will help guide the development of Biofidelity's portfolio of molecular diagnostic products based on its breakthrough ASPYRE technology, which enables simple, decentralized multi-gene testing in a fraction of the time and at a fraction of the cost of current technologies.

With the ability to perform ultra-sensitive detection of panels of DNA and RNA mutations from tissue or blood using existing real-time PCR platforms, ASPYRE provides comprehensive actionable results in a matter of hours. Biofidelity expects to launch ASPYRE-Lung (formerly Identi-Lung), its first commercial diagnostic assay, later this year through its recently established US headquarters and cancer diagnostic laboratory in Research Triangle Park, NC.

Dr. Barnaby Balmforth, Chief Executive Officer of Biofidelity, commented, "Biofidelity's disruptive technology is designed to revolutionize access to best-in-class cancer diagnostics, breaking down barriers to better screening, monitoring and treatment for all cancer patients. Dr. Mace Rothenberg, Dr. Hesham Abdullah and Dr. Jerald Radich have an extraordinary track record of service to cancer patients at the world's leading pharmaceutical companies and research centers, while Andrea Conners and Phylicia Woods have been tremendous advocates for patients and for access to precision medicine. We are greatly honored and encouraged by their commitment to support the potential of ASPYRE to provide oncologists with rapid, clinically actionable data to enable the right cancer treatment to be prescribed at the right time."

Biofidelity's scientific advisors include:

Dr. Mace Rothenberg is former Chief Medical Officer of Pfizer, where he led Pfizer's Worldwide Medical & Safety organization responsible for ensuring patients, physicians, and

regulatory agencies were provided with information on the safe and appropriate use of Pfizer medications.

Prior to his role as CMO, Dr. Rothenberg was Head of Clinical Development & Medical Affairs for Oncology at Pfizer from 2008 to 2016 and Chief Development Officer for Oncology from 2016 to 2018. His organization was responsible for the successful development and regulatory approval of 11 new cancer medicines, including IBRANCE®, the first CDK 4/6 inhibitor for patients with HR+/HER2- advanced breast cancer, and XALKORI®, the first targeted medicine developed for patients with ALK+ non-small cell lung cancer. Prior to joining Pfizer, Dr. Rothenberg spent 25 years in academia where he focused on early-stage drug development, clinical trial design, and the evaluation of new therapies for gastrointestinal cancers.

Hesham A. Abdullah, MD, MSc, is SVP and Head of Oncology Global Clinical Development at GSK, where he oversees end-to-end strategic development and delivery of GSK's oncology clinical-stage portfolio. Dr. Hesham has guided the development and registration of multiple oncology products including Iressa®, Lynparza™, Tagrisso®, Imfinzi™, Calquence®, Lumoxiti™, Zejula®, Blenrep and Jemperli.

Prior to leading oncology development at GSK, Dr. Abdullah rebuilt the Late-Stage Immuno-Oncology Development and Oncology Global Regulatory Sciences functions at AstraZeneca. He started his biopharmaceutical career at Amgen in 2006, subsequently joining AstraZeneca in late 2010. He has over 16 years of oncology and immuno-oncology drug development experience.

Dr. Jerald Radich is a Member of the Clinical Research Division, Director of the Molecular Oncology Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine. He is chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group. He was the inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, and a past member of the Board of Scientific Counselors of the NIH Genome Research Institute.

Dr. Radich is the past-chair of the CML Committee of the National Comprehensive Cancer Network, a member of the European Leukemia Network CML committees, and is on the Scientific Board of the International CML Foundation and the Max Foundation. He leads the Laboratory Committee of the NCI AML Precision Medicine Initiative and the Foundation of the NIH's program in measurable residual disease in AML.

Dr. Radich's laboratory research centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia. In addition, the CLIA Molecular Oncology Lab provides the molecular diagnostic support for many institutional, U.S. Intergroup, international, and pharmaceutical trials. He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab's work on diagnosing and monitoring CML in the developing world.

Andrea Conners is the Executive Director of Patient Empowerment Network (PEN), a nonprofit organization dedicated to improving treatment outcomes and health equity for cancer patients and their care partners. Prior to joining PEN, Andrea dedicated her career to translating science and innovation within the global healthcare field to media and lay audiences working in global pharmaceutical, biotech, and academic organizations in the US and around the world in locations as diverse as Shanghai and Surrey.

Phylicia L. Woods, JD, MSW is the Executive Director of the Cancer Policy Institute (CPI) at the Cancer Support Community where she is responsible for all aspects of the CPI including legislative, regulatory, policy, and research priorities. She primarily focuses on health disparities, psychosocial care, emerging sciences, and clinical trials. Previously, Ms. Woods was a Director of Federal Relations at the American Cancer Society Cancer Action Network (ACS CAN), where she developed and executed strategies to ensure that federal legislation and other initiatives promoted access to preventive services and quality, affordable care for people impacted by cancer. Formerly, Ms. Woods was Counsel to Former U.S. Senator Claire McCaskill. Before working in the U.S. Senate, Ms. Woods served as a U.S. Peace Corps Volunteer in eSwatini (Swaziland) as well as a Legislative Assistant to Former U.S. Congressman Russ Carnahan. Ms. Woods earned a Juris Doctor at the University of South Carolina School of Law, and a Master of Social Work and a Bachelor of Arts in Psychology from Saint Louis University. Currently, Ms. Woods serves as Chair of Virginia's Fairfax County Commission for Women, which advises the county on policies and initiatives to promote gender equality, eliminate violence against women, and honor women and girls.

About Biofidelity

Biofidelity, a private company founded in 2019 in Cambridge, UK, is revolutionizing access to best-in-class cancer diagnostics, breaking down the barriers to better screening, monitoring and treatment for all cancer patients. Its disruptive diagnostic technology platform provides oncologists with clinically actionable data based on ultra-sensitive detection of markers recommended in cancer treatment guidelines, enabling them to prescribe the right cancer drug at the right time. It is designed to combine fast and easy-to-interpret results with affordability and straightforward adoption on existing laboratory infrastructure, enabling many more laboratories to offer high quality cancer diagnostics.

For more information, please go to www.biofidelity.com

For enquiries, please contact:

Biofidelity
Dr. Barnaby Balmforth, CEO
T: +44 1223 358652
E: info@biofidelity.com

Mo PR Advisory
Mo Noonan/ Jonathan Birt
Tel: +44 (0) 7876 444977 / (0) 7860 361746